We’ve recently updated our valuation analysis.

iCAD Valuation

Is ICAD undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for ICAD?

Other financial metrics that can be useful for relative valuation.

ICAD key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue0.7x
Enterprise Value/EBITDA-1.5x
PEG Ration/a

Price to Sales Ratio vs Peers

How does ICAD's PS Ratio compare to its peers?

The above table shows the PS ratio for ICAD vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPSEstimated GrowthMarket Cap
Peer Average0.6x
UPH UpHealth
0.2x18.3%US$35.1m
AUGX Augmedix
1.5x28.2%US$44.0m
NH NantHealth
0.5xn/aUS$30.9m
MTBC CareCloud
0.4x7.0%US$51.0m
ICAD iCAD
1.5x35.1%US$43.0m

Price-To-Sales vs Peers: ICAD is expensive based on its Price-To-Sales Ratio (1.5x) compared to the peer average (0.6x).


Price to Earnings Ratio vs Industry

How does ICAD's PE Ratio compare vs other companies in the US Healthcare Services Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a36.6%
n/an/an/a

Price-To-Sales vs Industry: ICAD is good value based on its Price-To-Sales Ratio (1.5x) compared to the US Healthcare Services industry average (2.3x)


Price to Sales Ratio vs Fair Ratio

What is ICAD's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

ICAD PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio1.5x
Fair PS Ratio3.3x

Price-To-Sales vs Fair Ratio: ICAD is good value based on its Price-To-Sales Ratio (1.5x) compared to the estimated Fair Price-To-Sales Ratio (3.3x).


Share Price vs Fair Value

What is the Fair Price of ICAD when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate ICAD's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate ICAD's fair value for valuation analysis.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst ICAD forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$1.67
US$8.17
+389.0%
82.3%US$23.00US$4.00n/a6
Nov ’23US$1.94
US$10.67
+449.8%
57.7%US$23.00US$6.00n/a6
Oct ’23US$2.10
US$10.67
+407.9%
57.7%US$23.00US$6.00n/a6
Sep ’23US$2.94
US$10.67
+262.8%
57.7%US$23.00US$6.00n/a6
Aug ’23US$3.64
US$13.50
+270.9%
38.0%US$23.00US$8.00n/a6
Jul ’23US$3.95
US$13.50
+241.8%
38.0%US$23.00US$8.00n/a6
Jun ’23US$3.79
US$13.83
+265.0%
34.8%US$23.00US$8.00n/a6
May ’23US$3.60
US$14.17
+293.5%
31.4%US$23.00US$10.00n/a6
Apr ’23US$4.49
US$14.50
+222.9%
28.9%US$23.00US$10.00n/a6
Mar ’23US$4.56
US$14.50
+218.0%
28.9%US$23.00US$10.00n/a6
Feb ’23US$5.61
US$19.00
+238.7%
23.7%US$25.00US$13.00n/a6
Jan ’23US$7.20
US$21.43
+197.6%
15.9%US$25.00US$15.00n/a7
Dec ’22US$7.44
US$22.38
+200.7%
16.9%US$30.00US$17.00US$1.728
Nov ’22US$10.49
US$23.75
+126.4%
11.7%US$30.00US$20.00US$1.948
Oct ’22US$10.76
US$23.75
+120.7%
11.7%US$30.00US$20.00US$2.108
Sep ’22US$12.18
US$23.75
+95.0%
11.7%US$30.00US$20.00US$2.948
Aug ’22US$14.66
US$24.33
+66.0%
11.1%US$30.00US$22.00US$3.649
Jul ’22US$17.56
US$24.50
+39.5%
10.7%US$30.00US$22.00US$3.9510
Jun ’22US$16.60
US$24.40
+47.0%
11.2%US$30.00US$21.00US$3.7910
May ’22US$18.04
US$24.40
+35.3%
11.2%US$30.00US$21.00US$3.6010
Apr ’22US$19.98
US$22.78
+14.0%
10.1%US$28.00US$20.00US$4.499
Mar ’22US$18.98
US$22.00
+15.9%
9.6%US$27.00US$20.00US$4.568
Feb ’22US$17.03
US$16.79
-1.4%
9.3%US$19.00US$14.50US$5.617
Jan ’22US$13.20
US$15.92
+20.6%
7.8%US$18.00US$14.50US$7.206
Dec ’21US$9.97
US$14.70
+47.4%
5.9%US$16.00US$13.50US$7.445

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.


Discover undervalued companies